There are currently 88 ongoing clinical trials involving Medulloblastoma
Of the 88 trials,35 trials are in Phase II
Furthermore, 60 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Medulloblastoma, an Oncology condition. The largest number of ongoing clinical trials for Medulloblastoma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Medulloblastoma-related drug trials.
National Cancer Institute US: The leading ongoing Medulloblastoma related clinical trial sponsor
National Cancer Institute US is the top sponsor for Medulloblastoma-related ongoing clinical trials.
Children's Oncology Group, Pediatric Brain Tumor Consortium, St. Jude Children’s Research Hospital Inc, Seattle Children's Hospital, and Atrium Health are among other notable clinical trial sponsors involved in Medulloblastoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Medulloblastoma
Carboplatin (Carbomax) and Carmustine are key marketed drugs involving Medulloblastoma.
Carboplatin (Carbomax) is a metalloheterocyclic derivative, acts as an anti-neoplastic agent. It functions via DNA Synthesis inhibitor’s mechanism of action. It is formulated as an injection solution for the intravenous route of administration. Carbomax is indicated for the treatment of advanced ovarian cancer, small cell lung cancer, head, and neck cancer, and genitourinary cancer, particularly in the testicular, bladder, and cervical cancer, medulloblastoma. Carboplatin is marketed in India by GLS Pharma Ltd.
Carmustine acts as an alkylating agent. It functions via the DNA Synthesis inhibitor’s mechanism of action. It is formulated as a lyophilized powder for solution intravenous route of administration. Carmustine is used as palliative therapy for brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors as a single agent, and for multiple myeloma in combination with prednisone. Carmustine was approved in 2021 and is marketed in the US by Meitheal Pharmaceuticals Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward